Retrospective analysis of passive safety surveillance data of dengue vaccine, qdenga (TAK 003) at private vaccination centers, during 2023 and 2024 dengue season in buenos aires, argentina
Completed
The TAK-003 vaccine, Qdenga, developed by Takeda, was approved by ANMAT in April 2023 and has been available in Argentina since November 2023 for individuals from 4 years old and without limit of age. Clinical trials demonstrate that Qdenga has a favorable safety profile, adequat…
Sponsor: Fundación Vacunar
Last updated Sep 10, 2026 16:00 UTC